John McRae
Endocrinology, Diabetes & Metabolism · Nashville, TNNPI 1245334333
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 140 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in TN, where the typical reported total is $2,871.
Across 140 payments — averaging $20.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$507
- Lilly USA, LLC$250
- Xeris Pharmaceuticals, Inc.$246
- Cequr Corporation$198
- Dexcom, Inc.$193
- Boehringer Ingelheim$127
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,845100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 30 | $507 |
| Lilly USA, LLC | 13 | $250 |
| Xeris Pharmaceuticals, Inc. | 12 | $246 |
| Cequr Corporation | 3 | $198 |
| Dexcom, Inc. | 8 | $193 |
| Boehringer Ingelheim | 7 | $127 |
| AstraZeneca | 7 | $118 |
| Sanofi-aventis U.S. LLC | 7 | $111 |
| Tandem Diabetes Care, Inc. | 5 | $110 |
| Insulet Corporation | 6 | $104 |
| Abbott | 5 | $102 |
| BETA Bionics, Inc. | 4 | $99 |
| Bayer | 4 | $93 |
| Medtronic | 5 | $91 |
| AbbVie | 4 | $87 |
| Amarin Pharma, Inc. | 3 | $60 |
| Esperion Therapeutics, Inc. | 2 | $50 |
| Ascendis Pharma Endocrinology Inc | 2 | $46 |
| BD | 1 | $36 |
| IBSA Pharma Inc. | 1 | $35 |
| Lifescan, Inc. | 2 | $30 |
| Clarus Therapeutics Inc. | 2 | $27 |
| Companion Medical, Inc. | 1 | $27 |
| Merck | 1 | $21 |
| Recordati_rare_diseases_inc. | 1 | $19 |
| Amgen | 1 | $18 |
| Radius Health, Inc. | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$115
How this compares
$2,845 in reported general payments places this provider in the 45th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 43 | $59,013 |
| JardianceEmpagliflozin | 20 | $32,505 |
| MounjaroTirzepatide | 28 | $29,247 |
| Cinacalcet Hcl | 16 | $14,025 |
| FiaspInsulin Aspart (Niacinamide) | 13 | $12,372 |
| Humalog Kwikpen U-100Insulin Lispro | 17 | $9,027 |
| Novolog FlexpenInsulin Aspart | 24 | $6,612 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $4,193 |
| NovologInsulin Aspart | 11 | $2,146 |
| Ultra-Fine Micro Pen NeedlePen Needle, Diabetic | 13 | $1,790 |
| LantusInsulin Glargine,hum.Rec.Anlog | 11 | $1,656 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 11 | $1,018 |
| Testosterone Cypionate | 22 | $908 |
| SynthroidLevothyroxine Sodium | 14 | $794 |
| Levothyroxine Sodium | 71 | $574 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $507 | $73,53167 claims |
| Boehringer IngelheimJardiance | $127 | $32,50520 claims |
| Lilly USA, LLCMounjaro | $250 | $29,24728 claims |
| Sanofi-aventis U.S. LLCLantus | $111 | $1,65611 claims |
| AbbVieSynthroid | $87 | $79414 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $57471 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
Other endocrinology, diabetes & metabolism in Nashville
- Craig WierumNashville$1.3M
- Terri JerkinsNashville$567K
- Michael CarlsonNashville$381K
- Kathryn DahirNashville$225K
- Rodney SnowNashville$181K
- Annis MarneyNashville$26K
- Emily NeelyNashville$21K
- Amanda DanielNashville$20K
- Juliana MatthewsNashville$15K
- Christopher BowmanNashville$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.